Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE versus ZIPSOR.
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Diphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms and inducing sedation via central H1 blockade.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
One tablet (naproxen sodium 220 mg / diphenhydramine hydrochloride 25 mg) orally every 8 hours as needed, not to exceed 2 tablets in 24 hours.
50 mg orally three times daily
None Documented
None Documented
Naproxen: 12-17 hours (mean ~14 hours); clinically, allows twice-daily dosing for sustained anti-inflammatory effect. Diphenhydramine: 4-10 hours (mean ~7 hours); shorter half-life supports sedative effect for sleep induction.
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Naproxen: renal excretion of naproxen and its metabolites (95% as unchanged drug and conjugated metabolites, primarily 6-O-desmethylnaproxen). Diphenhydramine: renal excretion of unchanged drug and metabolites (primarily as diphenylmethoxyacetic acid); approximately 50-60% eliminated in urine as unchanged drug and metabolites, with a small fraction in feces.
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category D/X
Category C
NSAID
NSAID